260 related articles for article (PubMed ID: 35316498)
21. [Genetic polymorphism of von Willebrand factor (VWF)-cleaving protease, ADAMTS13].
Kokame K
Brain Nerve; 2008 Nov; 60(11):1325-32. PubMed ID: 19069166
[TBL] [Abstract][Full Text] [Related]
22. Contribution of ADAMTS13-independent VWF regulation in sickle cell disease.
Hunt RC; Katneni U; Yalamanoglu A; Indig FE; Ibla JC; Kimchi-Sarfaty C
J Thromb Haemost; 2022 Sep; 20(9):2098-2108. PubMed ID: 35753044
[TBL] [Abstract][Full Text] [Related]
23. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A
Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376
[TBL] [Abstract][Full Text] [Related]
24. Exploring the "minimal" structure of a functional ADAMTS13 by mutagenesis and small-angle X-ray scattering.
Zhu J; Muia J; Gupta G; Westfield LA; Vanhoorelbeke K; Tolia NH; Sadler JE
Blood; 2019 Apr; 133(17):1909-1918. PubMed ID: 30692120
[TBL] [Abstract][Full Text] [Related]
25. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress.
Shim K; Anderson PJ; Tuley EA; Wiswall E; Sadler JE
Blood; 2008 Jan; 111(2):651-7. PubMed ID: 17901248
[TBL] [Abstract][Full Text] [Related]
26. Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation.
Dhanesha N; Prakash P; Doddapattar P; Khanna I; Pollpeter MJ; Nayak MK; Staber JM; Chauhan AK
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1829-37. PubMed ID: 27444201
[TBL] [Abstract][Full Text] [Related]
27. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19.
Turecek PL; Peck RC; Rangarajan S; Reilly-Stitt C; Laffan MA; Kazmi R; James I; Dushianthan A; Schrenk G; Gritsch H; Ewenstein BM; Mellgard B; Erdlenbruch W; Jain N; Binder NB; Mumford AD
Thromb Res; 2021 May; 201():100-112. PubMed ID: 33662796
[TBL] [Abstract][Full Text] [Related]
28. ADAMTS13 Retards Progression of Diabetic Nephropathy by Inhibiting Intrarenal Thrombosis in Mice.
Dhanesha N; Doddapattar P; Chorawala MR; Nayak MK; Kokame K; Staber JM; Lentz SR; Chauhan AK
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1332-1338. PubMed ID: 28495930
[TBL] [Abstract][Full Text] [Related]
29. Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura.
Shin Y; Miyake H; Togashi K; Hiratsuka R; Endou-Ohnishi K; Imamura Y
J Biochem; 2018 May; 163(5):381-389. PubMed ID: 29228282
[TBL] [Abstract][Full Text] [Related]
30. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
[TBL] [Abstract][Full Text] [Related]
31. Higher and lower active circulating VWF levels: different facets of von Willebrand disease.
Casonato A; Pontara E; Morpurgo M; Sartorello F; De Groot PG; Cattini MG; Daidone V; De Marco L
Br J Haematol; 2015 Dec; 171(5):845-53. PubMed ID: 26456374
[TBL] [Abstract][Full Text] [Related]
32. Platelet-free shear flow assay facilitates analysis of shear-dependent functions of VWF and ADAMTS13.
Kraus E; Kraus K; Obser T; Oyen F; Klemm U; Schneppenheim R; Brehm MA
Thromb Res; 2014 Dec; 134(6):1285-91. PubMed ID: 25201004
[TBL] [Abstract][Full Text] [Related]
33. Degradation of circulating von Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax consumptive coagulopathy.
Chung MC; Popova TG; Jorgensen SC; Dong L; Chandhoke V; Bailey CL; Popov SG
J Biol Chem; 2008 Apr; 283(15):9531-42. PubMed ID: 18263586
[TBL] [Abstract][Full Text] [Related]
34. Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood.
Donadelli R; Orje JN; Capoferri C; Remuzzi G; Ruggeri ZM
Blood; 2006 Mar; 107(5):1943-50. PubMed ID: 16293606
[TBL] [Abstract][Full Text] [Related]
35. The potential therapeutic benefit of targeting ADAMTS13 activity.
Eerenberg ES; Levi M
Semin Thromb Hemost; 2014 Feb; 40(1):28-33. PubMed ID: 24338607
[TBL] [Abstract][Full Text] [Related]
36. Shear stress and von Willebrand factor in health and disease.
Tsai HM
Semin Thromb Hemost; 2003 Oct; 29(5):479-88. PubMed ID: 14631548
[TBL] [Abstract][Full Text] [Related]
37. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
[TBL] [Abstract][Full Text] [Related]
38. A common mechanism by which type 2A von Willebrand disease mutations enhance ADAMTS13 proteolysis revealed with a von Willebrand factor A2 domain FRET construct.
Lynch CJ; Cawte AD; Millar CM; Rueda D; Lane DA
PLoS One; 2017; 12(11):e0188405. PubMed ID: 29186156
[TBL] [Abstract][Full Text] [Related]
39. von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli.
Murphy SJX; Lim ST; Hickey F; Kinsella JA; Smith DR; Tierney S; Egan B; Feeley TM; Murphy SM; Collins DR; Coughlan T; O'Neill D; Harbison JA; Madhavan P; O'Neill SM; Colgan MP; O'Donnell JS; O'Sullivan JM; Hamilton G; McCabe DJH
Thromb Haemost; 2021 Jan; 121(1):86-97. PubMed ID: 32932544
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of von Willebrand factor scissile bond cleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13).
Xiang Y; de Groot R; Crawley JT; Lane DA
Proc Natl Acad Sci U S A; 2011 Jul; 108(28):11602-7. PubMed ID: 21705658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
